Resources from the same session
Randomized, open-label, phase III study comparing irinotecan plus S-1 with S-1 alone in patients with advanced esophageal squamous cell carcinoma after failure of prior platinum- or taxane-based chemotherapy: Results of an interim analysis
Presenter: Jing Huang
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Randomized phase II study of S-1 and concurrent radiotherapy with versus without induction chemotherapy of gemcitabine for locally advanced pancreatic cancer (LAPC): Final analysis of JCOG1106
Presenter: Tatsuya Ioka
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiology
Presenter: Takuji Okusaka
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Prognostic factors in curative treatment of gallbladder cancer - Data of 950 cases of “The German- Registry”
Presenter: Thorsten Goetze
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Phase III study comparing intraperitoneal paclitaxel plus S-1/paclitaxel with S-1/cisplatin in gastric cancer patients with peritoneal metastasis: PHOENIX-GC trial
Presenter: Yoshiyuki Fujiwara
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Molecular characteristics of hepatocellular carcinomas (HCC) from different age groups
Presenter: Celina Ang
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Invited discussant abstracts LBA26, LBA27 and 616PD
Presenter: Eric Van Cutsem
Session: Gastrointestinal tumours, non-colorectal
Resources:
Presentation
Invited discussant abstracts 617PD, 618PD, 619PD and LBA28
Presenter: Florian Lordick
Session: Gastrointestinal tumours, non-colorectal
Resources:
Presentation
Final results of NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
Presenter: Li-Tzong Chen
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Efficacy, safety, and health-related quality of life (HRQoL) of regorafenib in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: Results of the international, double-blind phase 3 RESORCE trial
Presenter: Jordi Bruix
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.